Clinical trials: Vaccine Response
Smallpox
Expanded Dryvax Dilution Study in Previously Vaccinated Adults
The purpose of this study is to determine the safety and effect of diluting smallpox vaccine, making a larger number of doses in case smallpox is released into the environment.
- Trial name
- NCT00050505
- Testing
- Live vaccinia virus vaccine
- Where
- 7 sites in United States
- Volunteers
- 927 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination
The objective will be to analyze the development of cellular and humoral immunity against SARS-CoV-2 after administration of a third dose of mRNA-1273 (Moderna) vaccine in patients who have remained seronegative after the full…
- Trial name
- VAX-TRES (NCT04930770)
- Testing
- MRNA-1273
- Sponsor
- Maria Joyera Rodríguez
Follicular Lymphoma
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
This is a prospective biological study evaluating the persistence of COVID-19 vaccine and other vaccines' (zoster, diphtheria and tetanus)-induced immunity in a subgroup patient affected by Follicular Lymphoma requiring treatment…
- Trial name
- FIL_FollVax22 (NCT06070961)
- Testing
- Cellular immunity vs SARS-CoV-2, Humoral immunity vs SARS-CoV-2, Cellular immunity vs Varicella Zoster Virus
- Where
- 14 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Triple Negative Breast Cancer, Metastatic Breast Cancer
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
This research study is studying immunotherapy as a possible treatment for metastatic Triple Negative Breast Cancer (TNBC) in participants who are HLA-A2+.
- Trial name
- NCT03362060
- Testing
- Pembrolizumab, PVX-410
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Vaccine Response
Systems Biological Assessment of Statin Effect on Vaccine Responses
This study is being done to answer the question: Does the use of statin lipid-lowering medication change the effect of influenza vaccine? The research team will use the knowledge gained from answering this question to understand…
- Trial name
- NCT06024096
- Testing
- Atorvastatin, Quadrivalent seasonal influenza vaccine
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Emory University
HPV-positive Oropharyngeal Squamous Cell Carcinoma
Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC
This phase I, open-label, single-arm trial uses a "3+3" dose-escalation design to evaluate the safety, tolerability, and preliminary efffcacy of intranasal WSK-IM05 vaccine combined with tislelizumab as neoadjuvant therapy in…
- Trial name
- NCT07565740
- Testing
- WSK-IM05 (4×10^10 vp), WSK-IM05 (8×10^10 vp), WSK-IM05 (1.6x10^11 vp)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Measurement of Immune Response to Prevenar13, Measurement of Immune Response to Hepatitis A
PCV13 + Hepatitis A Vaccine for Adults
The present study explores whether a simultaneously given hepatitis A vaccine (Epaxal) will have an impact on the immune response to PCV13 (pneumococcal conjugate vaccine; Prevenar13) vaccine in adults.
- Trial name
- PCV13+HepA (NCT01926860)
- Testing
- Prevenar13, Hepatitis A vaccine
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
HIV Infections
Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B
24 healthy male and female volunteers who are at low risk of HIV infection and entered into the RISVAC02 study and were randomly allocated to receive 3 intramuscular injections of MVA-B at weeks 0, 4 and 16 will receive a…
- Trial name
- NCT01923610
- Testing
- Experimental
- Where
- 2 sites in Spain
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Meningitis, Meningococcemia
Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26
Study will evaluate the persistence of antibodies approximately three years after an initial dose of Menactra® vaccine in toddlers who participated in study MTA26 (NCT00643916) and age-matched Menactra naive participants.
- Trial name
- NCT00700713
- Testing
- Meningococcal polysaccharide diphtheria toxoid conjugate
- Where
- 13 sites in United States
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Dengue viruses infect millions of people throughout the tropics and subtropics each year. The development of a dengue vaccine is an important health priority.
- Trial name
- NCT02392325
- Testing
- rDEN1Δ30, rDEN2Δ30-7169
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
- Trial name
- NCT01059617
- Testing
- GSK Biologicals' FluLaval®, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Japanese Encephalitis
Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children
This study has aim to describe the immune response to the second dose of Japanese encephalitis chimeric vaccine (JECV) in children previously vaccinated with one dose of JECV 5 years ago.
- Trial name
- NCT01954810
- Testing
- Japanese encephalitis chimeric vaccine (JECV)
- Where
- Thailand
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Khon Kaen University
Chikungunya Virus Infection
Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
This is a multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and immunogenicity of a 2-injection vaccine Chikungunya virus (CHIKV) virus-like particle vaccine (CHIKV VLP) in healthy adults.
- Trial name
- NCT02562482
- Testing
- VRC-CHKVLP059-00-VP, VRC-PBSPLA043-00-VP
- Where
- 6 sites in Dominican Republic, Guadeloupe and 3 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
The purpose of this study is to compare the body's immune response when vaccines are given alone versus when vaccines are given along with the study drug called ixekizumab. The vaccines protect against pneumonia and tetanus.
- Trial name
- NCT02543918
- Testing
- Ixekizumab, Boostrix®, Pneumovax®23
- Where
- 3 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Covid19, Kidney Transplantation
Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients
Vaccination against SARS CoV-2 appears to be the best strategy today to control the COVID-19 pandemic. The first published studies with Pfizer, Moderna and Astra-Zeneca vaccines show very good vaccine protection in the general…
- Trial name
- COVATRANS (NCT04828460)
- Where
- France
- Volunteers
- 3,500 people
- Sponsor
- University Hospital, Strasbourg, France
Polio
Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in Bangladesh
Hypothesis: The immunogenicity of oral polio vaccine (OPV) will be enhanced in Bangladeshi infants who receive bicarbonate buffer at the time of polio immunization.
- Trial name
- NCT01579825
- Testing
- Buffer
- Where
- Bangladesh
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Influenza, Human
Tropical Influenza Control Strategies for the Elderly
TROPICS1 is a randomized, observer-blind, active comparator-controlled, single-center, Phase IV trial in 200 participants aged ≥65 years.
- Trial name
- TROPICS1 (NCT02655874)
- Testing
- Influenza vaccine, Tetanus-diphtheria-pertussis vaccine
- Where
- Singapore
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
Intestinal Permeability, Inflammation
Induction of Gut Permeability by an Oral Vaccine
This study evaluates the effect of an oral typhoid vaccine on disruption of the intestinal barrier and response of the immune system.
- Conditions
- Intestinal Permeability, Inflammation, Vaccine, Typhoid Fever
- Trial name
- NCT04083950
- Testing
- Vivotif Typhoid Oral Vaccine, Aspirin (Positive Control)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- USDA, Western Human Nutrition Research Center
Respiratory Syncytial Virus Infections
A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
The purpose of this study was to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of the respiratory syncytial virus (RSV) maternal vaccine compared to placebo, when administered in the…
- Trial name
- NCT04980391
- Testing
- RSV MAT
- Where
- 35 sites in United States, Brazil and 7 more
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans
Background: The immune response is how the body recognizes and defends itself against foreign and harmful substances. Researchers want to compare the immune responses between young and older healthy adults after they receive…
- Trial name
- NCT04852289
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute on Aging (NIA)